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Pericardial ﬂuid proteomic label-free quantiﬁcation
of diﬀerentially expressed proteins in ischemic
heart disease patients with systolic dysfunction by
nano-LC-ESI-MS/MS analysis†
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Junaid Ullah,a Satwat Hashmi,b Arslan Ali, *c Faisal Khan,c Shahid Ahmed Sami,d
Nageeb Basir,e Syeda Saira Bokhari,e Hasanat Sharif,d Hesham R. El-Seedifg
and Syed Ghulam Musharraf *ac
Left ventricular systolic dysfunction (LVSD) is common in patients with pre-existing ischemic heart disease
(IHD) and myocardial infarction. An untargeted proteomic approach is used to improve the understanding
of the molecular mechanisms associated with LVSD and to ﬁnd out potential proteomic signatures in
pericardial ﬂuid. The pericardial ﬂuid of IHD (n ¼ 45) patients was grouped into two categories according
to the left ventricular ejection fraction, LVEF $45 (n ¼ 33) and LVEF <45 (n ¼ 12), and analyzed by using
nano-liquid chromatography–mass spectrometry (nano-LC-MS/MS) technique. The nano-LC-MS/MS
analysis resulted in the identiﬁcation of 709 pericardial ﬂuid (PF) proteins in both normal and impaired
systolic functional groups (LVEF $45 vs. LVEF <45). Sixteen proteins were found to be diﬀerentially
expressed (p < 0.05, fold change >2) including 12 down-regulated and 4 up-regulated in the impaired
systolic functional group (LVEF <45) compared to the normal group (LVEF $45). Among the diﬀerentially
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expressed proteins the inﬂammatory marker albumin, atherosclerosis marker apolipoprotein A-IV and

DOI: 10.1039/d0ra08389e

hedgehog-interacting protein marker of angiogenesis were predominantly associated with the impaired
LVEF <45 group. KEGG pathway analysis revealed that the hedgehog (Hh) signalling pathway is up-
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regulated in LVSD reﬂecting the underlying molecular and pathophysiological processes.

Introduction
Cardiovascular disease (CVD) is one of the main causes of
mortality and disability worldwide. According to the World
Health Organization (WHO), in 2008 approximately 17.3 million
people died from cardiovascular disease and this will, expectedly, rise to 23.3 million annually by 2030.1 Ischemic heart
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disease (IHD) is the most prevalent condition among the CVDs.
Le ventricular systolic dysfunction (LVSD) is common in
patients with IHD.2 LVSD refers to an impairment of the le
ventricular contractility that results in reduced le ventricular
ejection fraction (LVEF) and cardiac output. Patients with LVSD
were at increased risk of death compared to subjects with
a normal LVEF.3 A 10% reduction in LVEF predicts a 39%
increase in all-cause mortality, hospitalization and an increased
heart failure risk.4 Prevalence of LVSD increases substantially
with age and is more prevalent in men (7.6%) as compared to
women (2.6%)5
The measurement of proteins in biological samples plays
a key role in the diagnosis and prognosis of patients that are at
high risk of diseases. Pericardial uid has been used to
understand the molecular mechanism of disease in a number of
studies.6 Pericardial uid (PF) is an ultraltrate of the plasma
and a biochemical window into the heart by which information
related to the pathophysiological status of the heart can be
obtained.7 Pericardial uid is present between the two layers;
parietal and visceral of the pericardium and is produced by the
visceral pericardium of the heart. Under normal conditions, it
measures about 15–50 mL in volume. Many diseases including
ischemic heart disease, infections, and idiopathic causes can
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increase the volume and change its composition.8 The proteomic analysis of pericardial uid may be an important tool to
nd out the pathophysiological mechanisms underlying cardiac
diseases and to nd out potential therapeutic targets.9 Several
proteomic signatures have been discovered and used in the
management of LVSD such as Brain Natriuretic Peptide (BNP),
which is released in the pericardial uid and serum by the
ventricles in response to increased wall tension or stretch of
cardiac chambers.10 The proteomic analysis of pericardial uid
in patients with lung bullae disease resulted in the identication of 1007 proteins which provided valuable insight into
disease mechanism.11 To the best of our knowledge, this is the
rst study constituting the proteomic proling of the pericardial uid in patients with LVSD with established IHD.
The present study aimed to uncover the diﬀerentially
expressed proteins in the pericardial uid by a label-free
quantitative proteomic approach in IHD patients with
impaired (LVEF <45) and normal (LVEF $45) systolic function.
The study will help to improve the understanding of the
molecular mechanisms associated with LVSD and to nd out
potential proteomic signatures.

Material and methods
Experimental design and statistical analysis
For the present study fourty ve patients (43 men and 2 women)
were recruited with conrmed ischemic heart disease (IHD) at
South city and Aga Khan University Hospital Karachi, Pakistan.
A written informed consent was taken from each patient before
coronary artery bypass gra (CABG). In this study, patients with
renal insuﬃciency, metabolic bone diseases, valvular disease
moderate to severe, constrictive pericarditis and inltrative,
hypertrophic or restrictive cardiomyopathies, established
pulmonary disease and malignancy were excluded. Twodimensional and Doppler echocardiography was used for the
assessment of le ventricular systolic function following ASE
guideline 2009. Patients were further categorized into two
groups according to the LV ejection fraction: group A was 33
patients with normal le ventricular systolic function (LVEF
$45), and group B was 12 patients with impaired le ventricular
systolic function (LVEF <45) as depicted in Table 1. The study
was approved by the Ethical Review Board (ERB) of the Aga
Khan University Hospital and Institutional Review Board (IRB)
of International Centre for Chemical and Biological Sciences
(ICCBS), University of Karachi, Pakistan. All procedures followed in this study were in accordance with the ethical principles of the 1964 declaration of Helsinki.
Sample collection and processing
Pericardial uid samples were collected from each subject in
pre-labeled clean and sterile falcon tubes. Samples were
centrifuged at 3500 rpm, for 15 min at 4  C to remove cellular
components. For further analysis aliquoted samples were
stored at 80  C in microcentrifuge tubes. Bicinchoninic acid
(BCA) procedure was followed for measurement of total protein
concentration according to the Kit protocol.12

© 2021 The Author(s). Published by the Royal Society of Chemistry
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Table 1

Baseline characteristicsa
(LVEF $45%)

(LVEF <45%)

N
Age [years; mean (SD)]
Body weight [kg; mean (SD)]

33
59.7  7.1
72.7  11.3

12
58.0  9.6
76.6  12.7

Medical history
Diabetes/non-diabetes
Hypertension/non-hypertension

18/15
23/10

9/3
7/5

Renal function
Creatinine [mg dL1; mean (SD)]
BUN [mg dL1; mean (SD)]

1.0  0.2
16.0  3.4

1.0  0.3
19.2  11.3

Echocardiographic parameters
LVEF [%; mean (SD)]

58.2  4.9

36.6  8

a

SD standard deviation, BUN blood urea nitrogen, LVEF le ventricular
ejection fraction.

FASP digestion
Each pericardial uid sample equivalent to 200 mg protein, were
digested using lter-aided sample preparation (FASP) method.13
In short, protein concentrates in 0.5 mL 10 kDa cutoﬀ centrifuge lters were mixed with 500 mL of 6 M urea in 0.1 M tris/HCl
and the samples were centrifuged at 14 000g for 25 min at 20  C.
Aer centrifugation, 10 mL of 0.1 M Dithiotreitol (DTT) was
added to the lters, and incubated at 56  C for 30 min. Then, 10
mL of 0.3 M iodoacetamide (IAA) was added to the lters, aer
which the samples were incubated for 30 min in darkness.
Finally, 2 mg of trypsin (MS Grade, Thermo Scientic) in 50 mL of
100 mM NH4HCO3 was added to each lter. The protein to
enzyme ratio was 50 : 1. Samples were incubated overnight at
37  C and peptides were released and collected by centrifugation at 14 000g at 20  C for 25 min.
LC-MS/MS analysis
The protein digest were dissolved in 0.1% TFA and 1 mL
(equivalent to 2 mg) was injected on a C18-reverse-phase trapping column (C18, Acclaim™ PepMap™ 100, 75 mm  2 cm,
particle size 3 mm, nanoViper, Thermo Fisher Scientic) and
was separated by C18-reverse-phase nano-LC column (75 mm 
15 cm Acclaim™ PepMap™ RSLC C18 column with 2 mm
particle size and 100 
A pore size, NanoViper, Thermo Fisher
Scientic), using Nano-UHPLC, (Dionex, UltiMate 3000
RSLCnano System, Thermo Scientic, USA) coupled to MaXis II
ESI-QTOF Mass spectrometer (Bruker Daltonics, Bremen, Germany). Buﬀers A and B contained 0.1% formic acid in ultra-pure
water and 0.1% formic acid in acetonitrile (ACN), respectively
were used for peptide elusion. ACN gradient at 300 nL min1
was used to separate peptides aer 6 min sample load at a ow
rate of 5 mL min1 with 2% B. Elution of the peptides were
achieved by applying a linear gradient of 1–35% B over 29 min,
with subsequent gradient increase to 95% B over 2 min, hold B
for 7 min at 95%, and then decreased to 2% B for 4 min followed
by 12 min equilibration at 2% B. Data dependent acquisition
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(DDA) was carried out in positive ion mode. The parameters
were set as follows: end plate oﬀset voltage was 500 V, capillary
voltage was 4500 V, dry gas ow rate was 4.0 L min1 and dry
temperature was 180  C. Scan mode for MS and MS/MS were
between 150 to 2200 m/z. The threshold for MS/MS was 2500
and cycle time of 3 s.

Open Access Article. Published on 23 December 2020. Downloaded on 9/23/2021 12:14:58 PM.
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Label-free quantication
Bruker Daltonics Compass Data Analysis Soware (version 4.4)
was used to generate the molecular feature list for each LC-MS/
MS run. The resulting molecular features were transferred to
ProleAnalysis Soware to calculate buckets. A bucket is characterized by its MH+ mass value, retention time, and intensity
values. The parameters for bucket calculation were set as,
retention time range 6–45 min, mass range 150–2200 m/z,
normalization with a quantile, value count of group attribute
within bucket were set as 2 and value count of bucket 30. Aer
bucket generation, peptide regulation ratios were calculated
using T-test and transferred to ProteinScape soware.
To link peptide regulation output with the identication
results, the LC-MS/MS raw data les of each run were converted
to (.xml) using Bruker Daltonics Compass Data Analysis Soware (version 4.4). The resulting xml les were imported to
ProteinScape soware for the Mascot Database search. Aer the
protein database search, peptide identication was linked to
their peptide regulation ratios by selecting the retention time
correction option and p-value <0.05 as assignment criteria.
Finally, protein regulation ratios were calculated from peptide
regulation ratios and a list of proteins includes quantication
information such as the number of peptides ratios, coeﬃcient
of variation (CV) values, and the regulation ratios were
generated.14
MS/MS data analysis using ProteinScape
Nano-LC-MS/MS raw data les of each run were converted to
(.xml) and were searched using the Mascot search engine
(Version 2.6, Matrix Science, London, UK) triggered by ProteinScape against Swiss-Prot database with the following
parameters: taxonomy lter was set to homo sapiens, for
proteolytic cleavages, trypsin was used with maximum missed
cleavages up to 1, oxidation of methionine as variable modications and carbamidomethyl of cysteine as xed modications
were allowed. Peptide mass tolerance was set at 0.08 Da and
fragment mass tolerance was set at 0.2 Da. Peptide charges were
set at +2, +3, and +4. The accepted FDR was set to <1%.

Paper
Length cutoﬀ 33 and expect value 1  103 were set as parameter for blastp-fast. Parameters for the gene ontology (GO)
annotations were set as; Hit lter 500, GO weight 5, HSP-Hit
coverage cutoﬀ 0, annotation cutoﬀ 55 and E-value-hit-lter 1
 106. The level 2 pie/bar chart conguration was used for
showing annotated sequences in GO graphs. The association
between diﬀerentially expressed quantied proteins with each
other and their interaction with other proteins were assessed by
the STRING EMBL soware (version 11.0, https://string-db.org/
). The medium condence score of 0.400 was used.16

Results
For the present study, workow is shown in Fig. 1. The data
acquisition stage consisted of pericardial uid sample analysis
through nano-LC-ESI-MS/MS by using the data dependent
acquisition (DDA) strategy. The statistical analysis stage was
used to nd out signicantly diﬀerentially expressed proteins in
both groups (LVEF $45 vs. LVEF <45) followed by the bioinformatics analysis (GO and KEGG) to understand the biological role of these proteins.
Label-free proteomics and identication of diﬀerentially
expressed proteins
A total of 709 pericardial uid proteins were identied using the
DDA strategy in both groups (LVEF $45 vs. LVEF <45) (Table
S1†). The annotated spectra of all the identied proteins along
with the diﬀerentially expressed proteins are given in the ESI
le.† For a better look, the double fold change for the log 2based values derived from the quotient (LVEF <45/LVEF $45) is
presented in Fig. 2 as a volcano plot, statistically determined by
a P-value <0.05, at 2.0-fold change. The identied proteins in the
two groups of the experiment (LVEF $45/LVEF <45) were
analyzed and compared, 16 proteins were found diﬀerentially
expressed, including 12 down-regulated and 4 up-regulated
proteins in impaired (LVEF <45) systolic function group as

Bioinformatic analysis
Label-free quantied proteins were further subjected to bioinformatic analysis, including gene ontology (GO) and KEGG
pathway analysis. The 16 diﬀerentially expressed proteins
sequence information was extracted from the online UniProt
knowledgebase database (https://www.uniprot.org/) and
retrieved in FASTA format. Functional classication of proteins
was done by gene ontology on the basis of biological process,
molecular process and cellular component using OmicsBox
(version 1.2, https://www.biobam.com/omicsbox/).15 HSP

322 | RSC Adv., 2021, 11, 320–327

Fig. 1 Workﬂow of the present study. First stage is the data acquisition
stage; it consisted of pericardial ﬂuid (PF) sample preparation and its
nano-LC MS/MS analysis using DDA strategy. The second stage is the
data analysis stage; it consisted of statistical analysis and bioinformatic
analysis (GO and KEGG pathway analysis).

© 2021 The Author(s). Published by the Royal Society of Chemistry
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and hedgehog-interacting protein were the most up-regulated
proteins. The results with protein name, accession number,
isoelectric point, sequence coverage, molecular weight, foldchange and t-test p-values are presented in Table 2.
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Functional classication of diﬀerentially expressed proteins

Volcano plot of peptide areas, derived from the quotient (LVEF
<45/LVEF $45) with log 2 fold-change (x-axis) versus log 10 p-value
(y-axis). The orange dots, located in the upper-left and upper-right
sections, corresponding to high fold changes and low p-values, indicate signiﬁcantly regulated signals while the gray dots indicate the
non-signiﬁcant diﬀerentially expressed signals. For the diﬀerentially
expressed signals, a p-value of <0.05 and fold change of >2 are set as
the signiﬁcant thresholds.

Fig. 2

compared to normal (LVEF $45) systolic function group. Serum
albumin, mesothelin, E3 ubiquitin-protein ligase SH3RF3, Rho
GTPase-activating protein 44 and serotransferrin were the most
down-regulated while AT-rich interactive domain-containing
protein 4A, zinc nger protein GLI2, zinc nger protein 831,

A GO classication was performed for the 16 signicant diﬀerentially expressed proteins in patients with normal (LVEF $45)
and impaired (LVEF <45) systolic function group as shown in
the pie chart at graph level 2 (Fig. 3 and Table S2†). The GO
analysis of diﬀerentially expressed protein revealed involvement
in multiple biological processes in both groups. The highest
proportion of (18%, 7 proteins: MTUS1, TRFE, PHF1, MSLN,
SH3R3, OSBL6, RHG44) sequences were found to be involved in
cellular processes followed by biological regulation (15%, 6
proteins: MTUS1, TRFE, PHF1, SH3R3, OSBL6, RHG44), and
metabolic processes (13%, 5 proteins: PHF1, MSLN, SH3R3,
OSBL6, APOA4), while the remaining functions such as
response to a stimulus; localization, signaling, developmental
process, cellular component organization, locomotion, immune
system process biological adhesion and multicellular organismal process, were observed in less proportions in both groups
(LVEF $45/LVEF <45). Diﬀerentially expressed, proteins were
also classied based on their molecular functions, such as
protein involved with binding (81%, 13 proteins: MTUS1, PHF1,
MSLN, EFC4B, GLI2, RHG44, TRFE, SRBP2, ARI4A, SH3R3,

Table 2 Diﬀerentially expressed proteins identiﬁed in ischemic heart disease patients with normal LV systolic function (LVEF $45) and impaired
LV systolic function (LVEF <45)

Accession

Protein

ALBU_HUMAN
TRFE_HUMAN
APOA4_HUMAN
MSLN_HUMAN
RHG44_HUMAN

Serum albumin
Serotransferrin
Apolipoprotein A-IV
Mesothelin
Rho GTPase-activating protein
44
Oxysterol-binding proteinrelated protein 6
Zinc nger protein GLI2
Sterol regulatory elementbinding protein 2
PHD nger protein 1
Zinc nger protein 831
EF-hand calcium-binding
domain-containing protein 4B
Nuclear pore complex protein
Nup205
Microtubule-associated tumor
suppressor 1
Hedgehog-interacting protein
E3 ubiquitin-protein ligase
SH3RF3
AT-rich interactive domaincontaining protein 4A

OSBL6_HUMAN
GLI2_HUMAN
SRBP2_HUMAN
PHF1_HUMAN
ZN831_HUMAN
EFC4B_HUMAN
NU205_HUMAN
MTUS1_HUMAN
HHIP_HUMAN
SH3R3_HUMAN
ARI4A_HUMAN

MW
[kDa]

Mascot
pI score

Sequence
coverage
#Peptides [%]

RMS90
[ppm]

Fold change log 2
(LVEF $45):
p(LVEF<45)
Value Regulation

69.3
77.0
45.4
68.9
89.2

5.9 3565.8
6.8 2660.8
5.3 461.2
6.0 76.2
6.1 51.1

62
43
12
3
2

73.9
50.9
32.6
5.4
1.1

42.24
44.56
44.87
572.57
12.74

5.02
2.09
1.86
4.60
2.26

0.0029
0.0006
0.0029
0.0001
0.0007

Down
Down
Down
Down
Down

106.2

6.5

38.4

2

2.1

36.23

1.89

0.0001 Down

167.7
123.6

6.9
8.7

37.7
34.2

2
1

1.5
1.0

664.68
1.51

4.47
1.50

0.005 Up
0.0147 Down

62.1
177.8
45.6

9.3
8.7
4.9

31.2
25.7
20.2

1
1
1

1.4
1.0
2.5

6.49
5.91
16.97

1.42
4.03
1.50

0.0001 Down
0.0009 Up
0.0147 Down

227.8

5.8

20.0

1

0.4

922.75

1.08

0.0116 Down

141.3

7.3

19.6

1

0.8

8.45

1.50

0.0147 Down

78.8
92.7

8.2
9.1

17.6
17.0

1
1

2.0
1.0

6.71
10.22

2.34
3.17

0.0184 Up
0.0001 Down

142.7

5.0

15.6

1

1.0

3.54

4.49

0.0042 Up

© 2021 The Author(s). Published by the Royal Society of Chemistry
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Fig. 3 Go annotation of “biological process” “molecular function” and “cellular component” analyze by OmicxBox (version 1.2, https://
www.biobam.com/omicsbox/).

OSBL6, APOA4, ZN831), transporter activity (12%, 2 proteins:
TRFE, OSBL6) and catalytic activity (6%, 1 protein: HHIP).
OmicsBox analysis, also classied the diﬀerentially
expressed proteins according to their cellular component. Most
of the proteins were assigned to the organelle (12%, 4 proteins
MTUS1, MSLN, NU205, OSBL6), followed by extracellular region
(12%, 4 proteins: TRFE, MSLN, APOA4, ALBU) and membrane
(9%, 3 proteins: MTUS1, MSLN, OSBL6), while the remaining
component such as extracellular region part, membrane part,
membrane-enclosed lumen, supramolecular complex and
protein-containing complex were observed in fewer
proportions.
KEGG pathway analysis
STRING was used to gain an insight into the interactive links
known to be associated with the 16 proteins expressed diﬀerentially in the dataset. Interactive links between the diﬀerentially regulated proteins could be traced as shown in Fig. 4. A
total of 8 RCTM/KEGG pathways were observed in the present
study. The suggested pathways of these diﬀerentially regulated
proteins are listed in Table 3, along with term ID, term denition, observed gene count, background gene count, FDR and
matching proteins within a network.

324 | RSC Adv., 2021, 11, 320–327

Interactive network analysis and association of 16 diﬀerentially
expressed pericardial ﬂuid proteins obtained from STRING (version
11.0, https://string-db.org/).
Fig. 4
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Table 3 Pathways of diﬀerentially expressed protein identiﬁed in ischemic heart disease patients with normal LV systolic function (LVEF $45) and
impaired LV systolic function (LVEF <45)
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KEGG/RCTM pathways

#Term ID

Term description

Observed gene count

Background gene
count

False discovery
rate

Matching proteins in
your network (labels)

HSA04340
HSA05217
HSA-381426

Hedgehog signaling pathway
Basal cell carcinoma
Regulation of insulin-like growth factor
(IGF) transport and uptake by insulin-like
growth factor binding proteins (IGFBPs)
Post-translational protein
phosphorylation
Metabolism of steroids
Plasma lipoprotein remodeling
Bile acid and bile salt metabolism
Hedgehog ‘on’ state

2
2
3

46
63
123

0.009
0.009
0.012

GLI2, HHIP
GLI2, HHIP
ALB, MSLN, TF

3

106

0.012

ALB, MSLN, TF

3
2
2
2

146
30
42
82

0.012
0.012
0.0157
0.0405

ALB, OSBPL6, SREBF2
ALB, APOA4
ALB, OSBPL6
GLI2, HHIP

HSA-8957275
HSA-8957322
HSA-8963899
HSA-194068
HSA-5632684

Discussion
Proteomics is used to perform quantitative as well as qualitative
analyses of a large array of proteins in biological samples.17
Recently, label-free quantitative proteomics (LFQP) has gained
more popularity as mass spectrometer's eﬃciency has signicantly improved. The LFQP becomes a widely applied approach
for identifying as well as quantifying diﬀerentially expressed
proteins. It increases the dynamic range of proteins 3 to 4 time
as compared to 2DE and is more sensitive and rapid than many
other proteomic methods.18
In the present study, we have found 16 signicantly diﬀerentially expressed proteins in LVEF $45 vs. LVEF <45. Among
the diﬀerentially expressed proteins 12 proteins down-regulated
in impaired (LVEF <45) systolic function group, including
serum albumin, serotransferrin, apolipoprotein A-IV, mesothelin, Rho GTPase-activating protein 44, sterol regulatory
element-binding protein 2, oxysterol-binding protein-related
protein 6, PHD nger protein 1, nuclear pore complex protein
Nup205, EF-hand calcium-binding domain-containing protein
4B, Microtubule-associated tumor suppressor 1, and E3
ubiquitin-protein ligase SH3RF3. While, the remaining 4
proteins were found up-regulated in impaired (LVEF <45)
systolic function group including, zinc nger protein 831, zinc
nger protein GLI2, AT-rich interactive domain-containing
protein 4A and hedgehog-interacting protein. One of the
down-regulated protein in patients with impaired (LVEF <45)
group is albumin. Albumin is a 66.5 kDa protein which is the
most abundant protein in plasma. Albumin plays a signicant
role in regulating plasma oncotic pressure and uid distribution throughout the body compartment.19 Serum albumin's
physiological properties include anti-inammatory, antioxidant, anticoagulant activity and regulating the transport of
cholesterol.20 Normal pericardial uid contains between one
quarter and one third of the protein of plasma and demonstrates a far higher proportion of albumin to other proteins in
the pericardial uid.21,22 Hypoalbuminemia, with serum
albumin levels less than 3.5 g dL1 (ref. 23) has been linked to

© 2021 The Author(s). Published by the Royal Society of Chemistry

several cardiovascular diseases such as coronary artery disease,
congenital heart disease, stroke and heart failure.24 Hypoalbuminemia has been reported in one-third of heart failure
patients with reduced ejection fraction (LVEF <45).25 In
concordance with the ndings in the serum, the present ndings suggest that the down-regulation of albumin in the pericardial uid is associated with impaired systolic function of the
le ventricle. Hence, it could be used as a potential risk marker
in identifying the patients with le ventricular systolic
dysfunction.
Another down-regulated protein in impaired (LVEF <45)
group is serotransferrin. It is an iron binding protein, responsible for transporting iron from sites of heme degradation and
absorption to those of utilization and storage.26 The serum level
of serotransferrin decreases in inammatory conditions such as
diabetes mellitus which in turn increases the risk of CVD.27 It
has been demonstrated that decrease level of plasma serotransferrin is associated with rheumatic valvular heart disease
(RVD),28 and coronary artery dilation (CAD) caused by Kawasaki
disease.29 The down-regulation of serotransferrin in impaired
(LVEF <45) group may be due to the inammatory response of
the body as its level also decreases in patients with CKD and
ESRD.30
Apo A-IV is another protein that is down-regulated in
impaired (LVEF <45) group. Apo A-IV, is an oligosaccharide
containing protein with a molecular weight of 46 kDa.31 Its
concentration in plasma is 15–37 mg dL1.32 Apo A-IV is
synthesized in the intestine and is incorporated into the
chylomicrons and secreted into the intestinal lymph during fat
absorption.33 Apo A-IV plays a signicant role in the lipid and
glucose metabolism.34 It also acts as anti-inammatory agent
and potentially exert its anti-atherogenic eﬀect35 by reverse
cholesterol pathway, which removes cholesterol from peripheral cells and transports it to the liver.36 Clinical studies have
demonstrated an inverse relationship between apo A-IV and
coronary artery diseases.37 Apo A-IV deciency is associated with
atherosclerosis, cardiovascular diseases, chronic pancreatitis,
malabsorption disorders38 and diabetes mellitus.39 Low Apo A-
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IV levels in these patients with systolic dysfunction as compared
to patients with preserved EF may point towards a disease
mechanism underlying the progression from preserved EF to
reduced EF.
Among the up-regulated diﬀerentially expressed proteins in
patients with impaired (LVEF <45) group is AT-rich interactive
domain containing protein 4A. It is also known as ARID4A or
retinoblastoma – binding protein 1 is encoded by the gene
ARID4A.40 Studies shows that ARID4A play a signicant role in
various types of cancer such as breast cancer and leukemia.
ARID4A binds with other proteins and play a key role in cell
proliferation and diﬀerentiation.41 Zinc nger protein 831
belongs to a large class of zinc nger proteins (ZNFs) is upregulated in impaired (LVEF <45) group. Zinc nger proteins
(ZNFs) have a key role in tissue development and diﬀerentiation. Alterations in ZNFs are involved in the development of
several diseases such as congenital heart disease, defects of the
cardiac outow tract and diabetes.42
KEGG network analysis with pathway enrichment identied
that the hedgehog signaling pathway is up-regulated in
impaired (LVEF <45) group as compared to the normal (LVEF
$45) group. Network analysis revealed that two up-regulated
proteins zinc nger protein GLI2 and hedgehog-interacting
protein are involved in hedgehog signaling (Hh) pathway. Hh
signaling pathway was rst identied as a key mediator of
organogenesis in invertebrates by Nusslein–Volhard and Wieschaus in 1980.43 Three Hh homologues have been discovered
in mammals in the early 1990s, including Indian hedgehog
(Ihh), Sonic (Shh) and Desert (Dhh). Sonic is one of the best
studied and most widely expressed during embryonic development as compared to Dhh and Ihh.44 Hh signaling pathway is
known to regulate cell diﬀerentiation and migration during
embryonic development but in post-natal life, the Hh signaling
can be recapitulated under several pathological conditions,
including cardiac ischemia.45 The absence of tissue specic Hh
signalling components reduces proangiogenic gene expression
and thus loss of coronary vasculature that leads to cardiomyocyte cell death and ventricular failure. The presence of
the Hh signalling pathway may protect and limit the extent of
myocardial ischemic damage.46 Many theories are postulated to
elucidate the regulation mechanism of Hh signaling pathway in
ischemic heart tissues. It has been shown that the expression of
hypoxia-induced factor-1 (HIF-1) and inammation in cardiac
ischemia, activate the Hh signaling pathway, resulting in
elevated expression of angiogenic and proangiogenic factors to
facilitate angiogenesis and neovascularization in ischemic
tissues.47 In concordance with the previous ndings, our results
also validate the recapitulation of Hh signaling pathway in
ischemic heart disease patients but more prominently in
impaired (LVEF <45) group.48 Considering that the Hh signaling
pathway is essential for the formation of new coronary vessels,
this nding signals an important adaptive mechanism in
humans with LVSD.49
KEGG pathway analysis also showed that pathways involved
in the Metabolism of steroids (pathway proteins: albumin,
oxysterol-binding protein-related protein 6, sterol regulatory
element-binding protein 2), plasma lipoprotein remodelling
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(pathway proteins: albumin, apolipoprotein A-IV) and bile acid
and bile salt metabolic pathways (pathway proteins: albumin,
oxysterol-binding protein-related protein 6) were downregulated in impaired (LVEF <45) group as compared to the
normal (LVEF $45) group.

Conclusion
In conclusion, sixteen proteins were found to be diﬀerentially
expressed between IHD patients with LVEF <45 and LVEF $45.
Among the diﬀerentially expressed proteins the inammatory
marker albumin, atherosclerosis marker apolipoprotein A-IV
and hedgehog-interacting protein marker of angiogenesis
were predominantly associated with impaired LVEF <45 group.
The KEGG pathway analysis revealed that the hedgehog
signaling pathway is up regulated in impaired LVEF <45 group.
These ndings suggest important associations of heart systolic
function with specic proteins reecting its underlying pathophysiological mechanisms, however, they need to be further
validated in a larger number of samples.
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